Key result
RV septal LGE linked to ~443% greater risk of VT/VF in biopsy-proven sarcoidosis.
Why the study?
Risk assessment in cardiac sarcoidosis remains challenging, prompting an exploration of the prognostic value of myocardial late gadolinium enhancement.
Does a risk stratification approach based on LGE features improve arrhythmic risk prediction compared to the Heart Rhythm Society classification system in patients with biopsy-proven sarcoidosis?
Population
324 patients with biopsy-proven sarcoidosis
Comparison
LGE extent, pattern, and location vs Heart Rhythm Society classification system
Design
Cohort study
Authors
Loading...
Supports improved discrimination over HRS criteria in sarcoidosis; leaves open whether it should guide management.
Observational (n=324)
No
Does a risk stratification approach based on LGE features improve arrhythmic risk prediction compared to the Heart Rhythm Society classification system in patients with biopsy-proven sarcoidosis?
Effect estimate: HR 5.43 (95% CI 2.61-11.30)
p-value: p=<0.001
A risk stratification approach based on LGE features significantly improves the prediction of life-threatening ventricular arrhythmias in patients with biopsy-proven sarcoidosis compared to the standard Heart Rhythm Society classification.
Azzu et al. (2025) conducted an observational in Biopsy-proven sarcoidosis (n=324). Late gadolinium enhancement (LGE) on the right ventricular septum vs. Absence of LGE on the right ventricular septum was evaluated on Ventricular tachycardia (VT) or ventricular fibrillation (VF) or appropriate device therapy (HR 5.43, 95% CI 2.61-11.30, p=<0.001). Late gadolinium enhancement on the right ventricular septum strongly predicted life-threatening ventricular arrhythmias (HR 5.43) in patients with biopsy-proven sarcoidosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: